The most prescribed anti-inflamatory drug Nimesulide was first developed by Helsinn Healthcare and is marketed world-wide.
NImesulide is available in the form of tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%).
The anti-inflammatory drug mechanism of Nimesulide should only be prescribed as second line treatment. It provides the fast onset of the analgesic action.
The rapid onset of the analgesic action is crucial for the patients with acute pain and also in case of treatment with systemic NSAIDs
The harmonized indications in the EU are acute pain, primary dysmenorrhoea. The dosage of Nimesulide ought to be used is 100 mg twice daily, the duration prescribed is 15 days to minimize the risk of hepatotoxicity.
The drug must be used under supervision by a licensed physician in accordance with the approved indications. Prescription of the Nimesulide must be based on assessment of the patients’ characteristics and needs.
Nimesulide is contraindicated in children below 12 years and in patients suffering from liver problems.
Betwinner
ReplyDelete